Therapeutic value and mechanistic action of PSPC1 in AML

$6.15M USD

Funder	NATIONAL CANCER INSTITUTE
Recipient Organization	University of Texas Hlth Science Center
Country	United States
Start Date	Jun 01, 2024
End Date	May 31, 2029
Duration	1,825 days
Number of Grantees	2
Roles	Co-Investigator; Principal Investigator
Data Source	NIH (US)
Grant ID	`10976257`

Grant Description

Summary Acute myeloid leukemia (AML) is a biologically and genetically heterogeneous hematopoietic malignancy characterized by the blockage of myeloid cell differentiation and uncontrolled proliferation of immature myeloid cells. Although treatment options for AML have progressed over the past few decades, the 5-year overall survival

of AML patients is still